WHO HIV Prevention Jab Rollout
WHO Recommends New Long-Acting Injectable HIV Prevention Tool
Table of Contents
The World Health Institution (WHO) has officially recommended a new long-acting injectable medication for HIV prevention, marking a meaningful advancement in the global fight against the virus. This proposal aligns with approvals from US health authorities, offering a new, discreet option for individuals seeking to protect themselves from HIV.
A New Era in HIV Prevention
The newly recommended injectable, known as LEN, offers a promising option to daily oral pills. This long-acting formulation provides a discreet and convenient method for HIV prevention, perhaps improving adherence and accessibility for many. The WHO’s endorsement signifies a crucial step towards diversifying the toolkit available for HIV prevention strategies worldwide.
Understanding LEN: A Closer Look
LEN is a long-acting injectable medication designed for pre-exposure prophylaxis (PrEP). Unlike daily pills, it is administered less frequently, offering a more sustained level of protection. This innovation is particularly significant for individuals who may struggle with the daily adherence required for oral PrEP. The US health authorities have already approved LEN in June, further validating its efficacy and safety profile.
Call for Immediate Implementation
While access to the LEN injection is currently limited outside of clinical trials, the WHO is urging governments, donors, and partners to integrate this new tool into national HIV prevention programs without delay. This call to action underscores the urgency and importance of expanding access to effective HIV prevention methods.the WHO highlights that LEN joins a growing arsenal of HIV prevention options. These include daily oral tablets, injectable cabotegravir (administered every two months), and the dapivirine vaginal ring. This expanding range of choices empowers individuals to select the prevention method that best suits their lifestyle and needs.
The WHO’s recommendation comes at a critical juncture, as global efforts to combat HIV/AIDS face significant funding cuts. Notably, the US President’s Emergency Plan for AIDS Relief (PEPFAR), a cornerstone program launched in 2003 and instrumental in combating the disease, particularly in Africa, has experienced substantial reductions.In response to these funding challenges, the WHO has also released new operational guidance aimed at sustaining priority HIV services. this guidance is crucial for ensuring that existing prevention and treatment programs can continue to operate effectively despite financial constraints.
Dr. Meg Doherty, Director of WHO’s Department of Global HIV, Hepatitis and STI Programmes, emphasized the critical need for action: “We have the tools and the knowledge to end AIDS…what we need now is bold implementation of these recommendations, grounded in equity and powered by communities.” Her statement highlights that while scientific advancements are vital, their impact hinges on equitable access and community-driven implementation.
The Persistent Challenge of HIV
HIV continues to be a major global public health issue. As of the end of 2024, an estimated 40.8 million people were living with HIV, with a significant majority, approximately 65%, residing in Africa. In the same year, an estimated 630,000 people died from HIV-related causes globally, and an estimated 1.3 million new infections occurred, including 120,000 among children.
on a more positive note, access to HIV treatment continues to expand. In 2024, 31.6 million people were receiving treatment, an increase from 30.3 million the previous year. Antiretroviral medication is essential for managing the virus, preventing the immune system from being compromised and ultimately leading to the onset of AIDS. The introduction of new prevention tools like LEN is vital to further curb new infections and move closer to ending the AIDS epidemic.